ZA202006324B - Lopinavir and ritonavir for the treatment of cervix disorders - Google Patents
Lopinavir and ritonavir for the treatment of cervix disordersInfo
- Publication number
- ZA202006324B ZA202006324B ZA2020/06324A ZA202006324A ZA202006324B ZA 202006324 B ZA202006324 B ZA 202006324B ZA 2020/06324 A ZA2020/06324 A ZA 2020/06324A ZA 202006324 A ZA202006324 A ZA 202006324A ZA 202006324 B ZA202006324 B ZA 202006324B
- Authority
- ZA
- South Africa
- Prior art keywords
- lopinavir
- ritonavir
- cervix
- disorders
- treatment
- Prior art date
Links
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 title 1
- 208000026735 cervix disease Diseases 0.000 title 1
- 229940120922 lopinavir and ritonavir Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1808564.7A GB201808564D0 (en) | 2018-05-24 | 2018-05-24 | Treatments |
| PCT/IB2019/054292 WO2019224779A1 (en) | 2018-05-24 | 2019-05-23 | Lopinavir and ritonavir for the treatment of cervix disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202006324B true ZA202006324B (en) | 2022-01-26 |
Family
ID=62812406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/06324A ZA202006324B (en) | 2018-05-24 | 2020-10-12 | Lopinavir and ritonavir for the treatment of cervix disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11738024B2 (https=) |
| EP (1) | EP3801509A1 (https=) |
| JP (1) | JP7344911B2 (https=) |
| CN (1) | CN112203656B (https=) |
| AU (1) | AU2019274812B2 (https=) |
| BR (1) | BR112020023964A2 (https=) |
| CA (1) | CA3100425A1 (https=) |
| GB (1) | GB201808564D0 (https=) |
| MX (1) | MX2020012656A (https=) |
| SG (1) | SG11202010138WA (https=) |
| WO (1) | WO2019224779A1 (https=) |
| ZA (1) | ZA202006324B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201808563D0 (en) | 2018-05-24 | 2018-07-11 | Univ Manchester | Treatments |
| GB201808564D0 (en) | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Treatments |
| GB201907305D0 (en) | 2019-05-23 | 2019-07-10 | Douglas Pharmaceuticals Ltd | Treatment of conditions |
| GB201917252D0 (en) * | 2019-11-27 | 2020-01-08 | Pharmaceutic compositions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8822857D0 (en) | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
| DK2269591T3 (en) * | 2000-01-19 | 2018-07-16 | Abbvie Inc | IMPROVED PHARMACEUTICAL FORMULATIONS |
| CA2445967A1 (en) | 2001-05-01 | 2002-11-07 | Abbott Laboratories | Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents |
| US20030129208A1 (en) | 2002-01-07 | 2003-07-10 | Alberts David S. | Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses |
| WO2004010937A2 (en) | 2002-07-26 | 2004-02-05 | Advanced Research & Technology Institute At Indiana University | Method of treating cancer |
| BR0302523A (pt) | 2003-07-23 | 2005-04-05 | Cristalia Prod Quimicos Farm | Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| CA2582559A1 (en) | 2003-11-28 | 2005-06-16 | The University Of Manchester | Treatment of hpv infections and cancer |
| WO2008088806A1 (en) | 2007-01-16 | 2008-07-24 | Johns Hopkins University | Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants |
| EP2280690A2 (en) | 2008-04-18 | 2011-02-09 | Nanobio Corporation | Methods for treating herpes virus infections |
| GB201006038D0 (en) | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
| KR20130139896A (ko) | 2010-09-08 | 2013-12-23 | 프로노바 바이오파마 너지 에이에스 | 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물 |
| GB201115635D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir and ritonavir |
| PL3060211T3 (pl) | 2013-10-23 | 2020-07-27 | The University Of Manchester | Leczenie nowotworu i łagodnych chorób proliferacyjnych |
| WO2016123541A2 (en) | 2015-01-30 | 2016-08-04 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of encephalitis infection |
| WO2019130341A1 (en) | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
| GB201808563D0 (en) | 2018-05-24 | 2018-07-11 | Univ Manchester | Treatments |
| GB201808564D0 (en) | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Treatments |
| GB201808567D0 (en) | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201808571D0 (en) | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201907305D0 (en) | 2019-05-23 | 2019-07-10 | Douglas Pharmaceuticals Ltd | Treatment of conditions |
| GB201917252D0 (en) | 2019-11-27 | 2020-01-08 | Pharmaceutic compositions |
-
2018
- 2018-05-24 GB GBGB1808564.7A patent/GB201808564D0/en not_active Ceased
-
2019
- 2019-05-23 CN CN201980034993.5A patent/CN112203656B/zh active Active
- 2019-05-23 CA CA3100425A patent/CA3100425A1/en active Pending
- 2019-05-23 MX MX2020012656A patent/MX2020012656A/es unknown
- 2019-05-23 AU AU2019274812A patent/AU2019274812B2/en active Active
- 2019-05-23 US US17/055,048 patent/US11738024B2/en active Active
- 2019-05-23 BR BR112020023964-0A patent/BR112020023964A2/pt unknown
- 2019-05-23 WO PCT/IB2019/054292 patent/WO2019224779A1/en not_active Ceased
- 2019-05-23 EP EP19732473.4A patent/EP3801509A1/en active Pending
- 2019-05-23 JP JP2020565864A patent/JP7344911B2/ja active Active
- 2019-05-23 SG SG11202010138WA patent/SG11202010138WA/en unknown
-
2020
- 2020-10-12 ZA ZA2020/06324A patent/ZA202006324B/en unknown
-
2023
- 2023-06-30 US US18/216,937 patent/US20240148729A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019274812A1 (en) | 2020-12-10 |
| SG11202010138WA (en) | 2020-11-27 |
| US20210213015A1 (en) | 2021-07-15 |
| CN112203656A (zh) | 2021-01-08 |
| CN112203656B (zh) | 2024-09-27 |
| AU2019274812B2 (en) | 2024-12-05 |
| US11738024B2 (en) | 2023-08-29 |
| JP7344911B2 (ja) | 2023-09-14 |
| MX2020012656A (es) | 2021-02-02 |
| BR112020023964A2 (pt) | 2021-02-23 |
| CA3100425A1 (en) | 2019-11-28 |
| GB201808564D0 (en) | 2018-07-11 |
| US20240148729A1 (en) | 2024-05-09 |
| JP2021525266A (ja) | 2021-09-24 |
| WO2019224779A1 (en) | 2019-11-28 |
| EP3801509A1 (en) | 2021-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4218640T3 (en) | Systems for the treatment of disease states and disorders | |
| IL288214A (en) | Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders | |
| ZA201906904B (en) | Therapeutic agent for phosphodiesterase inhibition and its related disorders | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| ZA202006324B (en) | Lopinavir and ritonavir for the treatment of cervix disorders | |
| IL271072A (en) | Devices and methods for the treatment of body surface disorders | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| HUE059752T2 (hu) | A danon betegség és az autofágia egyéb rendellenességeinek kezelésére szolgáló módszerek | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| IL276485A (en) | Intrathecal epinephrine formulations and methods for treating the disease | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| IL269400A (en) | Medicines and preparations for the treatment of eye disorders | |
| IL284032A (en) | 3 beta-(benzyloxy)-17 alpha-methyl-paragan-5-en-20-one for use in the treatment of cognitive disorders | |
| EP3371154A4 (en) | HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | |
| IL276697A (en) | 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders | |
| HK40052939A (en) | Lopinavir and ritonavir for the treatment of cervix disorders | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
| CA3253199A1 (en) | Devices and methods for the treatment of body surface disorders | |
| HK40028798A (en) | Devices and methods for the treatment of body surface disorders | |
| HK1260601A1 (en) | Heterocycle derivatives and their use for the treatment of cns disorders | |
| HK40023930A (en) | Therapeutic agent for phosphodiesterase inhibition and its related disorders | |
| GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |